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A B S T R A C T
Amorphous solid dispersions (ASDs) are found to be a well-established strategy for overcoming limited aqueous
solubility and poor oral bioavailability of active pharmaceutical ingredients (APIs). One of the main parameters
affecting ASDs physical stability is the API solubility in the carrier, because this value determines the maximal
API load without a risk of phase separation and recrystallization. Phase-diagrams can be experimentally obtained
by following the recrystallization of the API from a supersaturated homogeneous API-polymer solid solution,
commonly produced by processes as solvent casting or comilling, which are very time-consuming (hours). The
work deals with the construction of a temperature-composition EFV-Soluplus® phase diagram, from a thermal
study of recrystallization of a supersaturated solid solution (85 wt% in EFV) generated by spray drying. This
supersaturated solution is kept at a given annealing temperature to reach the equilibrium state and the amount
that still remains dispersed in the polymer carrier at this equilibrium temperature is determined by means of the
new glass transition temperature of the binary mixture. From our knowledge, this is the first study employing a
fast process (spray drying) to prepare a supersaturated solid solution of an API in a polymer aiming to determine
a temperature-composition phase diagram. The EFV solubility in Soluplus ranges from 20wt% at 25 °C to 30wt
% at 40 °C. It can be a very useful preformulation tool for researchers studying amorphous solid dispersions of
Efavirenz in Soluplus, to assist for predicting the stability of EFV-Soluplus ASDs at different EFV loadings and
under different thermal conditions.
1. Introduction
One of the biggest challenges facing the pharmaceutical world today
is the poor aqueous solubility of many drugs. When a drug is ad-
ministered orally, if the clinical dose of the drug cannot be dissolved in
the available volume of gastrointestinal fluids, the drug will show a
poor oral absorption, which leads to a weak bioavailability [1].
The crystalline form of a drug offers the advantage of high purity
and physical or chemical stability. However, a large amount of external
energy is required to break the drug crystal lattice in dissolution. The
amorphous state, on the other hand, exhibits a disordered structure in
comparison to the crystalline form and possesses higher free energy
(thermodynamic driving force), which consequently is reflected by
higher apparent water solubility, dissolution rate, and oral absorption.
However, due to a lower thermodynamic stability, the main challenge
of amorphous form is evidenced: stabilization against drug re-
crystallization tendency both on in vivo dissolution and storage [2,3].
To retain the solubility advantage of the amorphous state, amorphous
solid dispersions (ASDs) have been proposed as an effective strategy to
“kinetically stabilize” amorphous drugs [4]. ASDs refer to drug - carrier
systems, where the drug is dispersed at a molecular level in the carrier,
usually an amorphous polymer [5,6]. ASDs can be produced by several
processes such as freeze-drying [7,8], hot-melt extrusion [9,10], rotary
solvent evaporation [11]; ball milling [12]; cryo-milling [13]; super-
cooling [14] and spray drying [6,15,16].
The choice of the carrier is a critical parameter for ASDs because it
impacts several factors such as molecular mobility, preparation
methods and the physical/chemical stability of the amorphous form. To
stabilize an ASD thermodynamically, it is of great importance to dis-
perse molecularly the drug in the carrier because, if the drug is mole-
cularly dispersed in the carrier at concentrations below the drug solu-
bility in the carrier at a fixed temperature, this system is, in theory,
thermodynamically stable. Consequently, for the rational development
of ASDs, it is essential to know the solubility of the drug in the carrier
because this value determines the maximal drug load without a risk of
phase separation and recrystallization [17,18].
However, measuring the API solubility in polymers is still a chal-
lenge due to the high polymers viscosity that hampers the solubility
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equilibrium achievement (equilibrium between a crystalline solute and
its solution), and makes difficult the experimental construction of so-
lubility curves in a low time consuming [9]. For this reason, different
methods have been developed to determine the solubility of APIs in
polymeric carriers: estimation of the solubility of a API in a polymer
from the solubility of the API in a low molecular weight liquid, che-
mically analogue to the polymer [19]; methods based on thermal
analysis such as the melting point depression method [20] and the
dissolution end point method [21].
Theoretically, melting of a crystalline API occurs at the temperature
(Tm) when the chemical potential of the crystalline API equals to the
chemical potential of the molten API. The melting point depression
method explores the depressed melting point of the API in the presence
of a miscible polymer [19]. Assuming that the amorphous API behaves
as a solvent and thus by extending the equations presented by Flory-
Huggins systems, it is possible to relate solubility of a API in an
amorphous polymer to melting point depression of the API [22]. The
onset of the melting endotherm is considered as the equilibrium solu-
bility temperature of the given composition. The choice of the melting
onset eliminates the impact on Tm of particle size and preparation
method of the physical mixtures. However, the onset only marks the
beginning of the API dissolution in the polymer but does not provide
information concerning the amount of API in the binary mixture that
can be dissolved at that respective temperature [19]. Progressing the
protocol for thermal analysis, the cryomilling of the physical mixtures
was proposed in order to compensate the slow dissolution kinetics by
reducing the size crystals prior to DSC experiments [5]. However,
cryomilling is a longstanding process and have some limitations to
control and to standardize particle characteristics such as size, mor-
phology, shape and surface properties [23]. In contrast, the dissolution
endpoint method enables the measurement of the endpoint of the dis-
solution step and thus might be more accurate [24]. The end point
value represents the melting point of the final composition, assuming
complete mixing has occurred. The disadvantage of this method is its
strong dependence on the particle size. If the particle size is not suffi-
ciently small, the melt is not able to reach its equilibrium state during
heating. This may result in a higher dissolution end point, leading to
underestimation of the API-polymer solubility.
The mentioned methods follow the dissolution kinetics of APIs into
polymers at under saturated concentration solutions. Another way to
determine the API-polymer solubility is to reach faster the equilibrium
solubility by following the recrystallization (recrystallization method)
of the API from a supersaturated homogeneous API-polymer solid so-
lution [13,19]. The demixing kinetics of APIs from supersaturated
systems is expected to be much faster than the dissolution kinetics of
APIs into under saturated systems. This difference arises directly from
the molecular mobility in the polymer matrix, which is higher in su-
persaturated API-polymer solutions than in under saturated ones.
The supersaturation of the API into the polymer can be obtained
from a physical mixture of crystalline API and polymer carrier by dif-
ferent techniques such as film casting method [19] and comilling
[13,24] that forces the miscibility of the two compounds to reach su-
persaturation. The supersaturated glass solution is then loaded in a DSC
analyzer and annealed above its Tg during a sufficient time to complete
the demixing process: release the excess of API in the mixture and reach
the equilibrium solution concentration at the annealing temperature.
We propose here to prepare supersaturated API-polymer solid so-
lutions by spray drying as an alternative to determine API-carrier so-
lubility from demixing, because it is a fast process (some seconds)
compared to other ones commonly used as solvent casting or comilling,
which are very time-consuming (hours) [25]. From our knowledge, this
is the first study employing spray drying to prepare a supersaturated
solid solution of an API in a polymer aiming to determine a tempera-
ture-composition phase diagram by following the recrystallization of
the API from a supersaturated homogeneous API-polymer solid solu-
tion. The binary mixture case-control study is Efavirenz-Soluplus®. The
chosen API, Efavirenz (EFV), is classified as class II API according to the
biopharmaceutical classification system (BCS) [26] with high perme-
ability and poor-water solubility water (below 10 µg/mL) in its crys-
talline form[27]. EFV is recommended by the World Health Organiza-
tion [28] as a first-line anti-HIV API, largely used as a non-nucleoside
reverse transcriptase inhibitor as part of antiretroviral therapies.
However, it exhibits low oral bioavailability (40–45%) [29,30]. Am-
phiphilic polymers have gained much attention in recent studies to
inhibit recrystallization in ASDs. Composed by a hydrophilic unit
(contact with aqueous media) and a hydrophobic unit (contact with the
API), Soluplus® (SOL) is an example of amphiphilic polymer [8].
2. Experimental section
2.1. Materials
Efavirenz, EFV, ((S)-6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-
(trifluoromethyl)-2H-3,1-benzoxazin-2-one, Fig. 4) was kindly provided
by Cristalia Ltd (Itapira, Brazil). Soluplus®, SOL, (polyvinyl capro-
lactam-polyvynil acetate-polyethylene glycol graft copolymer/PCL-
PVAc-PEG, Fig. 4) was provided by BASF corporation (Ludwigshafen,
Germany). Ethanol used as organic solvent in the preparation of solid
dispersions was purchased from Carlo ERBA Reagent (Italy). For the
purpose of analysis, distilled and purified water (conductivity of 18.2
MΩ.cm at 23 °C) was obtained by the purification system Milli-Q
(classic Purelab DI, MK2, E3lga, UK). Physicochemical characteristics of
API and polymer are summarized in Table 1.
2.2. Supersaturated EFV ASD
2.2.1. Preparation
A supersaturated amorphous solid dispersion (SD) EFV: SOL was
prepared by spray drying with a drug load proportion of 85:15 wt%.
A Buchi B-290 mini spray dryer (Buchi Labortechnik AG, Flawil,
Switzerland) equipped with Inert Loop B-295 and an integrated two-
fluid 0.7 mm nozzle was used to produce the ASD samples.
Solvent choice is an essential step in the spray dryer process, and it
was based on high solubility of API and polymer, generation of a feed
solution with acceptable viscosity, low toxicity and high volatility to be
easily evaporated during the drying of the liquid droplets. Ethanol re-
spects these specifications and was thus used as the common solvent.
The feeding solution was prepared by dissolving EFV in a 10% (w/w)
solution of SOL in absolute ethanol 99%.
Compressed nitrogen was used as the drying/carrying gas with a
flow rate of 600 L/h. The solution feed rate was ranged from 50 to
117 kg/h, the inlet air temperature was set to 80 ± 2 °C and the re-
sultant outlet temperature (59 ± 2 °C) was determined by the inlet
temperature and relative factors such as air and liquid flow rates.
Ethanol was continuously condensed in the process for further disposal.
The dry powder was recovered in a cyclone.
2.2.2. Solid state characterization
2.2.2.1. Thermal analysis (DSC). Thermal analyses were performed by
using a DSC Q200 with the base module and mDSC (TA instruments,
USA). On this, it was used a RCS90 cooling system which explains that
we can precisely control the cooling rate. Nitrogen was used as the
purging gas at 50mL/min, the analysis was made in non-hermetic
Table 1
Physico-chemical properties of products [31,32].
Molecular weight (g/mol) Melting point (°C) Density (g/cm3)*
Efavirenz 315.68 136–141 1.39
Soluplus® 90,000–140,000 – 1.18
* Determined experimentally by gas pycnometry.
aluminum pans, indium standards were used for enthalpy and
temperature calibration and an empty aluminum pan was used as a
blank. Concerning mDSC, sapphire was used to calibrate in CP. Samples
were heated with a rate of 2 °C/min. To obtain endothermic peaks and
analyze the apparent API-polymer miscibility, samples were heated
from 10 to 150 °C.
Moreover, experiments were also done on modulated-DSC to de-
termine glass transition temperatures of SOL, EFV and their mixture. In
these analyzes, the samples were heated at 2 °C/min from 10 to 150 °C,
with a modulation period of 40 s and an amplitude of 0.2 °C.
2.2.2.2. Cristallinity studies (PXRD). Powder X-ray diffraction patterns
were obtained by X’Pert Panalytical X-ray diffractometer (Philips, USA)
using CuKα radiation, putting 40mA of current and 45 kV of voltage.
The recording spectral range was set at 7–50° with a measuring step
(angular deviation between 2 consecutives points) of 0.0167° and an
acquisition time of 100 s per point. In addition, the powder was rotated
in its sample holder (1 s/revolution) during the acquisition of the
results.
2.2.2.3. Fourier transform infrared spectroscopy (FTIR). FTIR
investigations were realized on a Thermo Scientific Nicolet 5700
spectrometer. The samples were premixed with KBr using mortar and
pestle at 10% of the samples in KBr and the discs were produced by
compressing the powders at a working pressure of 1 t. The scanning
range was 4000–400 cm−1 with a 4 cm−1 resolution.
2.2.2.4. Surface morphology studies (SEM). SEM images of pure SOL,
pure EFV and solid dispersions were obtained using a scanning electron
microscope Philips XL30 ESEM-FEG (Philips, USA) with acceleration
voltage of 20 kV. Samples were fixed on a support using a double-sided
adhesive and covered with platinum using a high-resolution SEM
coated spray Polaron SC7640 (Quorom Technologies, England).
2.2.2.5. Raman mapping. Raman mapping was performed using a
Raman confocal microscope 300AR Alpha-AFM (Witec, Germany),
equipped with a laser at a wavelength of 532 nm and the analyses
were conducted at room temperature. Samples were analyzed by a 50×
objective with a lateral resolution of 432 nm and an axial resolution of
1320 nm. A surface (10× 10 μm) and deep mapping (12× 10 μm)
were used to predict drug and polymer distribution. Images obtained in
3D representing special distribution of the chemical species present in
the sample.
2.2.3. API-polymer solubility determination by recrystallization
The supersaturated SD was loaded into the DSC analyzer and an-
nealed at different temperatures below the Tm (melting point) of the
API under investigation (EFV) for 2–28 h to recrystallize the excess of
drug in the mixture and to reach equilibrium solubility. After annealing,
the sample was cooled to 10 °C and ramped at a rate of 2 °C/min to
determine the T g (glass transition temperature) of the annealed mate-
rial.
The recrystallization method is illustrated in Fig. 1 that presents a
schema of DSC running. Run 1 (first heat cycle) represents a change in
the solid state evidenced by an unique glass transition temperature of
the binary mixture, followed by an exothermic phenomenon (re-
crystallization). Run 2 (isotherm) aims to reach the equilibrium state
for the sample at a given annealing temperature. In turn, Run 3 is the
cooling step. Finishing the cycle, Run 4 (second heat cycle) gives the
new glass transition temperature of the binary mixture, corresponding
to the API amount that still remains dispersed in the polymer carrier at
the equilibrium temperature, which corresponds to the melting tem-
perature of this mixture TMIXm .
Annealing temperature and annealing time are essentials para-
meters and play an important role in the recrystallization method. At
lower annealing temperatures, a longer time is required to reach the
equilibrium state. The reason is probably a slower demixing kinetics
due to an insufficient molecular mobility, leading consequently to
slower API diffusion in the polymer matrix [13]. Completing the DSC
analysis, the new equilibrium dissolution concentration of the API re-
maining dispersed in the polymer was calculated using the Gordon-
Taylor equation [33,34].
2.3. Theoretical considerations
2.3.1. Prediction of the amorphous solid dispersion glass transition
temperature (TMIXg )
Gordon-Taylor equation is used to estimate the theoretical glass
transition temperature of the mixture TMIXg . It is calculated based on the
individual contributions of weight fraction and glass transition tem-
perature of each component in the binary mixture, without considering
the intermolecular interactions between them. Applying Gordon-Taylor
equation, the TMIXg is described by Eq. (1).
= + −+ −T W T K W TW K W. . (1 ).. (1 )MIXg PA PAg PA POgPA PA (1)
TPAg and TPOg are the API and polymer glass transition temperatures,
respectively. WPA is the API mass fraction in the mixture. K can be
defined as a parameter characterizing the intermolecular interactions
between both components resulting in the curvature of the evolution
and is defined by Eq. (2) [33]. A value of 1 for K means that the in-
teractions between both components are similar to the ones of the pure
components.
=K T ρT ρ..PAg PAPOg PO (2)
Densities of the drug and polymer, ρPA and, ρPO respectively, are
defined in Table 1.
2.3.2. Solubility curve fitting
Flory-Huggins modeling was used to construct the solubility curve,
which can estimate API solubility at a range of annealing temperatures
(see Table 2). The calculated data (Eq. (3)) were compared to the
Fig. 1. Principle of DSC analysis for recrystallization method.
Table 2
Glass transition temperatures of solid dispersion and pure components de-
termined by DSC and Gordon-Taylor equation.
WPA TMIXg (°C) ± 2 °C
Gordon Taylor equation DSC
0.00 – 79.9
0.40 62.8 62.2
0.70 49.6 47.1
0.85 47.2 36.7
1.00 – 36.2
experimental results obtained with the DSC protocol.
Binary interactions between polymer and API are commonly de-
scribed by Flory-Huggins parameter (χ) obtained from the solubility
curve. Immiscibility between the components is represented by a po-
sitive χ, while miscibility is indicated by a negative χ [13,35,36].
⎜− = − ⎛⎝⎜ +⎛⎝ − ⎞⎠⎟ + ⎞⎠⎟T T RH ν λ ν χ ν1 1 ∆ . ln 1 1 .MIXm PAm PAm PA PO PO2 (3)
TMIXm is the mixture melting temperature (in our case annealing
temperature at which equilibrium is measured), TPAm is the melting point
of the pure API, H∆ PAm is the melting heat of the pure API, R is the ideal
gas constant, λ is the molar volume ratio of the polymer and the API,
νPA and νPoare the volume fractions of the API and the polymer, re-
spectively. The volume fractions νi can be calculated according Eq. (4):
= + −ν
W
W Wi
ρ
ρ ρ
1PA PA
i
PA PO
i
(4)
3. Results and discussions
3.1. Supersaturated ASD characteristics
Solid states of samples were characterized by XRD analysis. The
XRD patterns obtained for pure SOL, unprocessed EFV crystals and SD
sample were depicted in Fig. 2. As expected, SOL is completely amor-
phous in nature (absence of any peaks on its diffractogram). Un-
processed EFV crystals exhibit principal sharp diffraction peaks at 2θ of
12.20°, 17.50°, 21.35° and 30.00° which represents characteristic peaks
for crystalline nature of EFV in accordance to the literature [37]. SD
sample did not show peaks of Bragg’s, which confirmed that it became
amorphous during spray-drying process.
The Raman spectra of the individual components (SOL and EFV)
and SD EFV were carried out to understand the drug distribution inside
polymer matrix (Fig. 3). SOL spectrum showed characteristic peaks
around 2987 cm−1 and 2900 cm−1 due to CeH stretching bands. For
EFV spectrum, characteristic peaks at a wavelength around 3100 cm−1
and 2250 cm−1 due to amine group NeH and CeC triple bond re-
spectively, were identified. SD Raman spectrum revealed all EFV and
SOL vibrations bands in the binary mixture. Still in Fig. 3, 3D images
represent a scan of the characteristic peak of each component in a SD
sample region (10 µm× 10 μm). It confirms the presence of SOL and
EFV and their good distribution with however a better uniformity for
SOL. In fact, the drug concentration in SD corresponds to a super-
saturated state of EFV in SOL and this EFV excess might be distributed
in amorphous clusters in the sample as suggested by EFV spot (yellow
area observed in 3D Raman imaging of EFV peak in Fig. 3).
FTIR spectra for EFV, SOL and SD are exhibited in Fig. 4. Pure SOL
spectra shows distinctive peaks in accordance to the literature [38]:
around 3675 cm−1 due to the hydrogen bonds O-H group, 2987 cm−1
and 2900 cm−1 due to CeH stretching bands, 1735 cm−1 and
1635 cm−1 corresponding to carbonyl bonds C]O group and
1406 cm−1 to CeOeC stretching vibrations. In turn, the characteristic
peaks previously reported for EFV [37] were also identified here:
around 3320 cm−1, 1600 cm−1, 2250 cm−1, 1750 cm−1 and
1250 cm−1 due to the amine group NeH, CeC triple bond, C]C bond
and CeF stretching vibrations, respectively. The spectral analysis of SD
confirmed that the characteristic peaks for the pure components were
present in the binary mixture, without modifications like shifts or dis-
appearance of peaks that could suggest specific interactions between
EFV and SOL components.
Microstructure morphologies of the spray-dried SOL and SD are
represented in Fig. 5. Spray-dried amorphous EFV were not observed by
SEM because, during production, the dry powder remained adhered to
the column wall due to the low T g (TPAg =36.1 °C) of amorphous pure
EFV. SOL spray-dried particles took a nearly spherical shape and had a
wrinkled appearance (Fig. 5A). In comparison, the “wrinkled collapsed
morphology” of SOL spray-dried particles was completely affected by
the presence of EFV (Fig. 5B). Indeed, SD particles are mostly spherical
with seemingly smooth surfaces without surface discontinuities, which
suggests a good mixture between the two amorphous components. SD
particles are constituted by some fused interconnected particles, which
could be explained by a still low T g since this sample contains a ma-
jority of the API that has a very low T g. Besides composition, the feed
concentration plays an important role in defining spray-dried mor-
phology [37]. Spray-dried SOL particles were generated from a feed
concentration of about 10% (w/w). In this case, the solid concentration
is low and then, through the evaporation process, the droplet surface
remained wet for a longer time creating hollow particles with a thin
solid skin that could deflate resulting in a wrinkled morphology. With
the API incorporation in the SOL solution, SD were generated from a
feed concentration of about 43% (w/w), what leads the droplets to dry
faster, developing a dried hard surface and preventing subsequent de-
flation and shrinkage.
3.1.1. API-polymer solubility determination by recrystallization
As proposed here, a supersaturated EFV-SOL solution with 85wt%
EFV (SD) was successfully prepared by spray drying. The glass transi-
tion temperatures of SD sample and pure components were determined
by DSC (Table 3). SD revealed a single and distinctive mixture glass
transition temperature (TMIXg ) in the reversing heat flow signals, which
indicates a single relaxation process, homogeneity and mixing at mo-
lecular level between the components in the supersaturated EFV-SOL
solution produced by spray-drying. DSC results are in good agreement
with XRD, Raman microscopy and FTIR results already presented [39].
The experimental TMIXg is compared (Table 2) with the theoretical
value calculated by the Gordon-Taylor equation previously detailed.
The parameter K is determined from Eq. (2) with the data from Table 2
and an apparent linear variation of Tg is achieved with a K close to 1
(1.03). The gap between experimental and theoretical (Gordon-Taylor)
Tg values increased with the increase of the EFV loading in the solid
dispersions. For the sample with 85 wt% of EFV, this difference is even
more significant. This could be explained by the large amount of EFV in
the sample, which is possibly responsible for disturbing the measure of
TMIXg due to the low value of ΔCP (0.16 J/g/K).
The high API load SD produced by spray drying was annealed from
90 °C until 130 °C to promote the recrystallization of excess EFV
amount. The choice of this temperature range was based on the mole-
cular mobility in the mixture, which became slower for the lowest
temperature and for the melting point of pure API. For instance, the
mDSC corresponding to 120 °C showed a mixture glass transition (TMIXg )
in Run 1 at 36.7 ± 3 °C followed by a recrystallization which starts atFig. 2. XRD diffractograms of pure compounds and spray-dried dispersion.
about 90 °C and continues until 120 °C. In Run 2 (isotherm), the sample
is heated during 2 h at 120 °C and then, it is cooled (Run 3). The step 2
is essential, because it favors the recrystallization of the remaining
excess EFV in order to reach the equilibrium state.
Once reached the equilibrium state, the sample was rescanned (Run
4) in the same conditions as the first cycle. It is detected a higher second
mixture glass transition (TMIXg =51.2 ± 3 °C) by a decrease in C∆ p
(0.32 J/g/K for Run 1 and 0.16 J/g/K for Run 4). This increase in the
TMIXg value and the smaller amplitude of C∆ p is expected to be due to the
reduction of amorphous API amount in the SD that recrystallized in
comparison with the Run 1.
The new EFV composition can be determined from Gordon-Taylor
equation. Table 3 regroups the saturated EFV concentrations at equi-
librium obtained for all annealing temperatures.
In the case of lower temperature than 110 °C, 2 h wasn’t enough to
reach the saturation equilibrium because of the slower kinetic of de-
mixing. In that case, the time required to reach the saturation equili-
brium had to be increased to 28 h.
Flory-Huggins model (Eq. (3)) was used to estimate the χ parameter
by lowering of theTg mixture temperature. The Eq. (3) is expressed in a
linear form for which χ is the slope of the obtained line (Fig. 6A). The
full line represents the linear regression of the data obtained with the
Fig. 3. 3D images and spectra from Raman spectroscopy of EFV, SOL and SD.
Fig. 4. FTIR spectra chemical formulas of pure components and solid dispersion.
least squares method and the dashed lines, in the same figure, re-
presents the limit of the 95% confidence interval (CI95%) for the slope.
The number of data used for the regression was decreased until all used
data are in this confidence interval. Finally, the χ parameter of Flory-
Huggins obtained is −1.165 with CI95%= [−1.70;−0.63]. A negative
χ parameter represents attractive API-polymer interaction [9]. Fig. 6B
presents the best fit of Flory-Huggins model with the corresponding
limits of χ confidence interval, as represented in Fig. 6A. To refine these
results, a polynomial fitting is also represented. The two fitting models
are in good agreement between them for low temperatures and give the
solubility curve of EFV in SOL. Thanks to these plots, it is possible to
identify regions of kinetic and thermodynamic stability. For example,
approximately 20 wt% (Flory-Huggins model) of EFV is soluble in SOL
at room temperature (25 °C). It means that a thermodynamic stability
should be achieved at room temperature for API loads lower than 20wt
%. In contrast, a high API load SD with 85wt% of EFV might be phase
separate and eventually recrystallize at 25 °C.
The lower temperature, the more difficult the determination of the
solubility curve, since the time required to reach the saturation equi-
librium is relevant due to slow kinectic of demixing. Although there is
no thermodynamic stability, the sample was still stable from the kinetic
point of view. As showed in Table 3, below 110 °C, the slow molecular
mobility makes the demixing process slower and then, a longer time
was required to reach the saturation equilibrium (28 h in our experi-
ments).
This method can not be applied for the lowest temperature given by
the crossing point between the solubility and Gordon-Taylor curves. In
our case, the crossing point for the Flory-Huggins model is 63.4 °C, what
means that, if the annealing is done under this temperature, it would
result in an abrupt reduction of molecular mobility and consequently of
the demixing process avoiding the reach of saturation equilibrium [13].
Fig. 5. SEM images of SOL (A) and SD (B).
Table 3
Equilibrium saturated concentration of EFV in SOL at different temperatures
(W )PA
Annealing temperature (°C) Annealing time (h) TMIX
g during Run 4
(°C)
WPA
90 28 55.0 0.58
100 28 54.9 0.58
110 2 52.2 0.64
120 2 51.2 0.66
125 2 47.1 0.75
130 2 45.9 0.78
137 – – 1.00
Fig. 6. (A) Estimation of Flory-Huggins parameter χ by linear regression (B)
Phase diagram of EFV-SOL.
4. Conclusion
Spray drying is one of the main processes capable of being scaled-up
into large manufacturing scale to produce ASDs but it could be de-
monstrated in this work that this process also represent an interesting
alternative to produce supersaturated solid solutions, from which API-
polymer solubility is determined from demixing, because it is a fast
process compared to other ones commonly used to produce super-
saturated solid solutions as solvent casting or comilling.
A supersaturated solid solution containing high API load (85 wt%
Efavirenz) in Soluplus® was generated by spray drying, in only few
seconds, and then exposed to a recrystallization protocol. The phase
diagram of Efavirenz (EFV)-Soluplus (SOL) obtained from this work can
be used to predict the stability of EFV-SOL ASDs at different EFV
loadings and under different thermal conditions. For example, samples
are stressed under different temperature conditions from room to 40 °C
in order to investigate physical stability. The EFV solubility in Soluplus
ranges from 20wt% (25 °C) to 30 wt% (40 °C). Amorphous solid dis-
persions of EFV in Soluplus containing more than 30wt% of EFV in
mass are supersaturated and their stability should be monitored over
storage from room to accelerated (40 °C) temperature conditions.
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